| Host: |
CHO cells |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human Interferon-gamma-protein was developed from cho cells. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 Mu m filtered concentrated (1mg/ml) solution in PBS, pH.2. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
Can be stored in working aliquots at°C-°C C for one month, or at-20°C C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: |
The ED (50) was determined by a cytotoxicity assay of HT29 cells and was found to be ≤ 0.5ng/ml, corresponding to a specific activity of ≥2x107 units/mg. NA |
| Gene Symbol: |
IFNG |
| Gene ID: |
3458 |
| Uniprot ID: |
IFNG_HUMAN |
| Immunogen Region: |
Mature chain |
| Immunogen: |
Optimized DNA sequence encoding Human Interferon gamma mature chain was expressed in CHO Cells NA |
| Immunogen Sequence: |
MKYTSYILAF QLCIVLGSLG CYCQDPYVKE AENLKKYFNA GHSDVADNGT LFLGILKNWK EESDRKIMQS QIVSFYFKLF KNFKDDQSIQ KSVETIKEDM NVKFFNSNKK KRDDFEKLTN YSVTDLNVQR KAIHELIQVM AELSPAAKTG KRKRSQMLFR GRRASQ NA |
| Tissue Specificity | Released primarily from activated T lymphocytes. |
| Post Translational Modifications | Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161. |
| Function | Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription. Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits. In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading. Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference. Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL. Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation. |
| Protein Name | Interferon GammaIfn-GammaImmune Interferon |
| Database Links | Reactome: R-HSA-877300Reactome: R-HSA-877312Reactome: R-HSA-8877330Reactome: R-HSA-8950505Reactome: R-HSA-9732724 |
| Cellular Localisation | Secreted |
| Alternative Protein Names | Interferon Gamma proteinIfn-Gamma proteinImmune Interferon proteinIFNG protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
